ZOM - Zomedica gains as new acquisition drives Q4 topline growth

The shares of Zomedica (NYSE:ZOM) have surged ~23% in the post-market Friday on above-average volume after the micro-cap animal health company reported more than $4M revenue for the final quarter and full-year 2021. While the company recorded no revenue in corresponding periods in the prior year, Q4 and full-year 2021 revenue reached $4.1M as PulseVet revenue grew to $4.0M during the quarter, indicating ~44% YoY growth as a standalone business. In October, Zomedica (ZOM) acquired PulseVet, a maker of non-invasive shock wave therapy treatment devices to animal health industry. Meanwhile, TRUFORMA product revenue jumped ~224% from the third quarter to $73K. The gross margin for the quarter reached ~74%. However, the cash and equivalents slipped to $195M from ~$271.4M at the end of Q3 2021. The company expects to release the full details of financials with its 10-K filing scheduled for March 01.

For further details see:

Zomedica gains as new acquisition drives Q4 topline growth